CIK 0001867096 · Large accelerated filer
Xeris Biopharma Holdings, Inc.
Sign in to watch- Ticker
- XERS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 871082097
- Phone
- 844-445-5704
- Business address
- 1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL, 60607
- 4 Grant or award Director acquired 50,000 shares (grant or award)
- 4 Grant or award Director acquired 50,000 shares (grant or award)
- 4 Grant or award Director acquired 50,000 shares (grant or award)
- 8-K Event Executive or director change · Shareholder vote results
- 4 Open-market buy Director bought 5,400 shares at $1.91 ($10,314)
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- ARS Other Annual Report to Security Holders
- DEFA14A Proxy Proxy Materials
- DEF 14A Proxy Proxy Statement
- 4 Other acquisition Director acquired 6,502 shares (other)
- 4 Other acquisition Director acquired 6,474 shares (other)
- 4 Other acquisition Director acquired 89,571 shares (other)
- 4 Option exercise Director acquired 215,600 shares (option exercise)
- 4 Open-market buy Director bought 4,500 shares at $2.16 ($9,720)
- S-8 Other Securities Offered to Employees in Benefit Plans
- 10-K Report Annual Report
- 8-K Event Material agreement · Results of operations · New debt or obligation · Other events
- SC 13G Stake Amended Statement of Ownership
- SC 13G/A Stake Amended Statement of Ownership
Page 10 of 18 · 346 filings